Hayman Rambaran, MD
Addiction Medicine · Paramus, NJNPI 1639295470
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Gilead at 41.1% of the total. Among addiction medicine clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 62 payments — averaging $33.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$852
- Indivior Inc.$343
- Braeburn Inc.$309
- Teva Pharmaceuticals USA, Inc.$174
- Neurocrine Biosciences, Inc.$143
- AstraZeneca$117
- plus $135 from 5 others
What the payments were for
- Food & beverage$2,074100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 8 | $852 |
| Indivior Inc. | 20 | $343 |
| Braeburn Inc. | 20 | $309 |
| Teva Pharmaceuticals USA, Inc. | 3 | $174 |
| Neurocrine Biosciences, Inc. | 3 | $143 |
| AstraZeneca | 1 | $117 |
| Alkermes, Inc. | 3 | $48 |
| Fisher Scientific Company L.L.C. | 1 | $37 |
| Neuronetics, Inc. | 1 | $18 |
| AbbVie | 1 | $18 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,074 in reported general payments places this provider in the 90th percentile of 57 addiction medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 68 | $9,932 |
| Gabapentin | 37 | $590 |
| Quetiapine Fumarate | 24 | $388 |
| Bupropion XlBupropion Hcl | 13 | $350 |
| Mirtazapine | 23 | $312 |
| Fluoxetine Hcl | 12 | $253 |
| Prazosin Hcl | 14 | $193 |
| Trazodone Hcl | 11 | $160 |
| Amlodipine Besylate | 13 | $64 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Paramus
- Joseph RanieriSewell$28K
- Peter KuponiyiEgg Harbor Township$8K
- Ruby KapadiaSaddle Brook$5K
- Richard HellanderCamden$3K
- Mohammed RahmanNeptune$2K
- David RussoBridgeton$1K
- Sailakshmi RamanujamToms River$1K
- Usman IjazClifton$943
- Lance GoobermanMerchantville$847
- Nola MahoneyHamilton$648
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.